Results 201 to 210 of about 1,171,277 (292)

A Diagnostic Challenge: Severe Thrombocytopenia During Streptococcal Cellulitis Revealing Previously Unrecognized Immune Thrombocytopenia. [PDF]

Cureus
Izadian Bidgoli A, Gomez Usatorres A, Gomez Usatorres HA, Gomez Veliz A.   +3 more
europepmc   +1 more source

Total body irradiation is associated with increased burden of cerebral microbleeds in haematopoietic stem cell transplant recipients

British Journal of Haematology, EarlyView.
Jure Hederih, Asad Charania, Camelia Vladescu, Ira Lacej, Richard Szydlo, Jiri Pavlu, Renuka Palanicawandar, Jose Ros‐Soto, Andrew Innes, Dragana Milojkovic, Eduardo Olavarria, Jane Apperley, Adam Waldman, Nichola Cooper   +13 more
wiley   +1 more source

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

British Journal of Pharmacology, EarlyView.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source

Thrombocytopenia, immune thrombocytopenia and idiopathic thrombocytopenic purpura

The Turkish Journal of Pediatrics, 2010
Sinasi Ozsoylu
doaj  

A Rare Case of Tirzepatide-Associated Immune Thrombocytopenia. [PDF]

Cureus
Rojas K, Ahmed A, Khan SJ, Singh GH.
europepmc   +1 more source

Nicotinic Acid Restriction Enhances the Therapeutic Benefit of NAMPT Inhibition in Small‐Cell Lung Cancer Models

Cancer Science, EarlyView.
Dietary NA restriction converts the effect of NAMPT inhibition from cytostatic to cytotoxic in SCLC in vivo. ABSTRACT Small‐cell lung cancer (SCLC) is an aggressive malignancy with limited therapeutic options. We previously showed that nicotinic acid riboside (NAR) sustains NAD biosynthesis in vivo and compensates for NAMPT inhibition in SCLC models ...
Kyoji Tsurumi, Miyuki Nomura, Mai Ouchi, Shigehiro Yagishita, Naohiko Kikuchi, Taku Sato, Mami Morita, Yoji Yamashita, Kayoko Hayashi, Tomoyoshi Soga, Akinobu Hamada, Tatsuro Fukuhara, Nobuhiro Tanuma   +12 more
wiley   +1 more source

Primary Sjögren's syndrome-associated immune thrombocytopenia: from pathogenesis to treatment. [PDF]

Front Immunol
Liu C, Zheng Z, He T, Zhang G, Fu G.
europepmc   +1 more source

Phase II Study of Cisplatin/Gemcitabine Plus Necitumumab for Squamous NSCLC After ICI‐Platinum Therapy (WJOG14120L)

Cancer Science, EarlyView.
WJOG14120L NESSIE evaluated cisplatin, gemcitabine, and necitumumab (CGN) as second‐line therapy after ICI‐based treatment in 46 patients with advanced squamous NSCLC. ORR was 26.1%, DCR 87.0%, and median PFS 4.4 months. Although the predefined ORR threshold was not met, CGN showed modest antitumor activity with manageable toxicity.
Hiroshige Yoshioka, Keita Mori, Nobuhisa Ishikawa, Hiroaki Kanemura, Koichi Azuma, Yukihiro Toi, Hiroshi Handa, Yosuke Tamura, Hiroaki Akamatsu, Haruko Daga, Masafumi Yamaguchi, Teppei Yamaguchi, Yuki Sato, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Takayasu Kurata   +15 more
wiley   +1 more source

Transient Platelet Elevation Following Oseltamivir Administration in Pediatric Chronic Immune Thrombocytopenia. [PDF]

Cureus
Yamamoto S, Furui Y, Okura E, Sakamoto K, Hirabayashi K, Saito S, Nakazawa Y.   +6 more
europepmc   +1 more source